1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Pricing and Reimbursement in Neurology -- Payer views

Pricing and Reimbursement in Neurology -- Payer views

  • January 2018
  • ID: 5355974
  • Format: PDF
  • By Firstword Pharma


Table of Contents

When first line treatments for neurological diseases such as Parkinson’s Disease (PD) and Multiple Sclerosis (MS) have been around for years, it’s understandable that when something new is approved, people want to try it. So, just how serious a stumbling block is the price gap between old and new proving to be for payers in the US and EU? Are pharma’s pricing justifications believed and accepted? And what are payer’s saying about the perceived change of tack from Roche regarding the pricing strategy for new arrival, Ocrevus?
The latest views and thinking from payers at the forefront of the pricing debate are shared in Pricing and Reimbursement in Neurology. Move beyond the general comments about cost and find out exactly what payers on both sides of the Atlantic think about the options available for PD, MS, epilepsy and amyotropic lateral sclerosis (ALS) and other neurological diseases.

Discover on this page…
• Key themes covered in the report
• What you will learn from the report
• Detailed table of contents
• Research objectives and methodologies employed in producing the report

Reasons to buy this report

Neurology is one area where the pricing debate rages on. The usual points on the real cost of development, the degree of improvement promised, and the volume of evidence available are all apparent. But there are key differences too.

The lack of biomarkers and the wide spectrum of symptoms mean prescribing decisions for neurology drugs can be particularly complex. Yet calls from payers for real-world data, more safety trials and head-to-head comparative data are getting louder and more urgent. And at the same time, questions continue to be asked about price parity in different countries, the risk of rising rather than falling costs and the problems associated with co-morbidity.
If some of the answers lie in proving efficacy and value to payers, exactly how can a body of evidence be built up when the cost of new drugs is unaffordable for many?

This report will enable you to:
• Tap into the latest payer views on drug pricing and reimbursement for neurology drugs.
• Look in detail at payer perceptions for four core neurological diseases: Parkinson’s, multiple sclerosis, epilepsy and amyotropic lateral sclerosis.
• Compare the views of expert payers in the US and the EU and understand the issues that impact them most.
• Discover what evidence payers want to support their neurology drug reimbursement decisions.
• Read payer comments on specific drug brands: Ocrevus, Xadago, Nuplazid and Radicava.
• Update your position by hearing current views from payers with a special interest in neurology.

Table of Contents
Executive Summary
Research Methodology and Objectives
Experts interviewed for this report

Pricing and Reimbursement in Neurological Diseases
• Pricing Issues in the EU
• Pricing Issues in the US
• Evidence Requirements for Reimbursement Decisions
• EU Payers
• US Payers

Amyotropic lateral sclerosis
• Why we are interested
• US Payer Views on the Pricing of Radicava

• Why we are interested
• Payer Views on the Pricing of Epilepsy Drugs
• EU Payers
• US Payers

Multiple sclerosis
• Why we are interested
• Payer Views on the Pricing of MS Drugs
• MS Drug Pricing in General: EU Payer Views
• MS Drug Pricing in General: US Payers
• Ocrevus (ocrelimzumab)

Parkinson’s disease
• Why we are interested
• Payer Views on the Pricing of Parkinson’s Disease Drugs
• PD Drug Pricing: EU Payer Views
• PD Drug Pricing: US Payer Views
• Xadago (safinamide)
• Nuplazid (pimavanserin)

Research Methodology and Objectives
This report explores payer attitudes to neurology drugs with a specific focus on Parkinson’s Disease, multiple sclerosis, epilepsy and amyotropic lateral sclerosis.

Analysis is based primarily on the insights and opinions of eight expert payers, including one from each of the major European markets (France, Germany, Italy, Spain and the UK) and three from the US. The interviews were conducted in December 2017. In order to share candid views, all interviewees chose to remain anonymous.
• French Payer: An academic general practitioner, this expert also worked in the Transparency Committee and was the leader for HTA evaluation for neurology in France.
• German Payer: General Manager in Purchasing Services at a 2,000-bed hospital who has served in various pharmacy and purchasing roles for more than 30 years.
• Italian Payer: A drug budget manager for a university hospital, and pricing and reimbursement expert for a regional committee.
• Spanish Payer: A hospital pharmacy director with 22 years of experience at local and regional levels, president of the local pharmacy commission and regional member.
• UK Payer: A neurology specialist pharmacist who manages neurological patients, as well as managing the formulary for neurology and working with commissioners in primary care.
• US Payer 1: Worked in the pharmacy benefit management industry for 18 years and is currently involved in a pricing and therapeutics committee.
• US Payer 2: A drug budget manager at a PBM who worked at a pharmacy company for the past 17 years and has experience of neurological disorders, oncology, and other specialities.
• US Payer 3: Pharmacy Director for a healthcare delivery system in the US and a licensed pharmacist with over 20 years of experience.

Key questions explored in this report include:
• How has the pricing of recently approved drugs for amyotropic lateral sclerosis, epilepsy, multiple sclerosis and Parkinson’s Disease been received by payers?
• Are prices for new drugs always too high or do they represent value money?
• What factors should pharmaceutical companies consider when making pricing decisions for neurological disease drugs?
• How do payers decide how much they are willing to pay for drugs that treat neurological diseases? Which factors influence their decision?
• How is cost versus effectiveness measured for drugs that treat neurological diseases?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019

5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019Summary5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 10 molecules. Out of which ...

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019’; Muscarinic Acetylcholine ...

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019" provides an overview ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on